Recent Quotes (30 days)

You have no recent quotes
chg | %

Merus Labs International Inc  

(Public, TSE:MSL)   Watch this stock  
Find more results for tse:msl
1.83
+0.09 (5.17%)
Delayed:   10:41AM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.74 - 1.84
52 week 1.08 - 2.68
Open 1.78
Vol / Avg. 536,962.00/774,086.00
Mkt cap 140.91M
P/E     -
Div/yield     -
EPS -0.06
Shares 77.00M
Beta 0.30
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -2.39% -6.09%
Operating margin 9.34% 19.40%
EBITD margin - 64.72%
Return on average assets -0.57% -1.93%
Return on average equity -0.84% -4.37%
Employees 6 -
CDP Score - -

Address

Suite 2110 100 Wellington St. West P.O. Box 151
TORONTO, ON M5K 1H1
Canada
+1-416-5933725 (Phone)

Website links

Description

Merus Labs International Inc. (Merus), formerly Envoy Capital Group Inc., is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. It has products in the area of urology/women's health, anti-infective, and wound care. Its products include Factive, Emselex/Enable, Vancocin and Collacare and Collexa. On January 6, 2012, the Company acquired 51% of Orbis Pharma Inc. On March 7, 2012, the Company completed the acquisition of the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets from Cornerstone Therapeutics Inc. In August 2013, the Company announced that the divestiture of the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets to Okana Ventures Inc.

Officers and directors

David D. Guebert CPA Independent Chairman of the Board
Ahmad Doroudian Executive Vice Chairman of the Board
Age: 50
Andrew Patient Chief Financial Officer
Ulrich Schoeberl Managing Director, European Operations
Barry Fishman Interim Chief Executive Officer, Director
Theresa Firestone Director
Robert S. Pollock Independent Director
Timothy G. Sorensen Independent Director
Michael S. Cloutier Non-Executive Independent Director